Exelixis' CELESTIAL Liver Trial Succeeds, But Can Cabozantinib Compete?
Executive Summary
CELESTIAL second-line liver cancer study is positive, but 4% response rate pales in comparison to PD-1 performance of Bristol's Opdivo and Merck's Keytruda.
You may also be interested in...
Keeping Track: FDA's Review Actions Carry On During Shutdown
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review
The latest drug development news and highlights from our US FDA Performance Tracker.
Exelixis: NCCN Change Supports Broader Use Of Cabometyx In Kidney Cancer
Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.